Astec Life Sciences Limited announced the outcome of its Board Meeting held on January 30, 2026. The Board approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months period ended December 31, 2025. The company also noted the Limited Review Reports from its statutory auditors with an unmodified opinion. In key personnel changes, the Board accepted the resignation of Ms. Mugdha Amol Khare as Chief Financial Officer, effective March 6, 2026, to pursue external opportunities. Concurrently, the Board approved the appointment of Mr. Deepak Jawaharlal Ochani as the new Chief Financial Officer, effective April 1, 2026. Mr. Ochani is a qualified Chartered Accountant with over 11 years of experience, including 9 years with the Godrej Agrovet group, bringing expertise in financial management, compliance, and governance. The financial results for the quarter ended December 31, 2025, show a revenue from operations of ₹12,472.03 lakh for both standalone and consolidated figures. The company reported a loss for the period, with a net loss after tax of ₹1,571.97 lakh standalone and ₹1,568.53 lakh consolidated for the quarter. The year-to-date figures for nine months ended December 31, 2025, also show a net loss after tax of ₹7,322.70 lakh standalone and ₹7,312.92 lakh consolidated.
